DK1720866T3 - Fremgangsmåde - Google Patents

Fremgangsmåde

Info

Publication number: DK1720866T3
Authority: DK; Denmark
Prior art keywords: course; action
Prior art date: 2004-01-15

Application number

DK04804455.6T

Other languages

English (en)

Inventor

Mathias Berwe

Joachim Rehse

Dirk Grotjohann

Christian Thomas

Original Assignee

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-15

Filing date

2004-12-31

Publication date

2011-11-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34716548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1720866(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-12-31 Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG

2011-11-21 Application granted granted Critical

2011-11-21 Publication of DK1720866T3 publication Critical patent/DK1720866T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Epidemiology (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK04804455.6T 2004-01-15 2004-12-31 Fremgangsmåde DK1720866T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102004002044A DE102004002044A1 (de)	2004-01-15	2004-01-15	Herstellverfahren
PCT/EP2004/014870 WO2005068456A1 (de)	2004-01-15	2004-12-31	Herstellverfahren

Publications (1)

Publication Number	Publication Date
DK1720866T3 true DK1720866T3 (da)	2011-11-21

Family

ID=34716548

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04804455.6T DK1720866T3 (da)	2004-01-15	2004-12-31	Fremgangsmåde

Country Status (32)

Country	Link
US (1)	US7351823B2 (da)
EP (1)	EP1720866B1 (da)
JP (2)	JP5311742B2 (da)
KR (1)	KR20130004257A (da)
CN (1)	CN1906191B (da)
AR (1)	AR047389A1 (da)
AT (1)	ATE518856T1 (da)
AU (1)	AU2004313694B2 (da)
BR (1)	BRPI0418405B8 (da)
CA (1)	CA2553237C (da)
CY (1)	CY1112565T1 (da)
DE (1)	DE102004002044A1 (da)
DK (1)	DK1720866T3 (da)
EC (1)	ECSP066703A (da)
ES (1)	ES2369140T3 (da)
GT (1)	GT200400277A (da)
HN (1)	HN2005000016A (da)
HR (1)	HRP20110796T1 (da)
IL (1)	IL176767A (da)
MA (1)	MA28290A1 (da)
MY (1)	MY138944A (da)
NO (1)	NO335553B1 (da)
NZ (1)	NZ548506A (da)
PE (1)	PE20050763A1 (da)
PL (1)	PL1720866T3 (da)
PT (1)	PT1720866E (da)
RU (1)	RU2383540C2 (da)
SI (1)	SI1720866T1 (da)
TW (1)	TWI340137B (da)
UY (1)	UY28718A1 (da)
WO (1)	WO2005068456A1 (da)
ZA (1)	ZA200605747B (da)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19962924A1 (de)	1999-12-24	2001-07-05	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) *	2001-06-20	2003-01-02	Bayer Ag	Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) *	2003-01-07	2004-07-15	Bayer Healthcare Ag	Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de)	2003-11-27	2005-06-23	Bayer Healthcare Ag	Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) *	2004-12-24	2006-07-06	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en)	2005-01-31	2006-08-02	Bayer Health Care Aktiengesellschaft	Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) *	2005-09-23	2007-03-29	Bayer Healthcare Ag	2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
AU2006299126B2 (en) *	2005-10-04	2012-06-28	Bayer Intellectual Property Gmbh	Novel polymorphous form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047558A1 (de) *	2005-10-04	2008-02-07	Bayer Healthcare Ag	Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de)	2005-10-04	2007-04-05	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005047564A1 (de) *	2005-10-04	2007-05-31	Bayer Healthcare Ag	Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
DE102006007146A1 (de)	2006-02-16	2007-08-23	Bayer Healthcare Ag	Aminoacyl-Prodrugs
DE102006039589A1 (de) *	2006-08-24	2008-03-06	Bayer Healthcare Ag	Aminoacyl-Prodrugs II
DE102006051625A1 (de) *	2006-11-02	2008-05-08	Bayer Materialscience Ag	Kombinationstherapie substituierter Oxazolidinone
DE102007028319A1 (de) *	2007-06-20	2008-12-24	Bayer Healthcare Ag	Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) *	2007-06-20	2008-12-24	Bayer Healthcare Ag	Substituierte Oxazolidinone und ihre Verwendung
WO2009018807A1 (de) *	2007-08-06	2009-02-12	Schebo Biotech Ag	Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie
US8706950B2 (en)	2008-03-01	2014-04-22	Kabushiki Kaisha Toshiba	Memory system
DE102008028071A1 (de) *	2008-06-12	2009-12-17	Bayer Schering Pharma Aktiengesellschaft	Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure
US20100168111A1 (en) *	2008-12-31	2010-07-01	Apotex Pharmachem Inc.	Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
US7816355B1 (en) *	2009-04-28	2010-10-19	Apotex Pharmachem Inc	Processes for the preparation of rivaroxaban and intermediates thereof
US8435989B2 (en) *	2009-04-28	2013-05-07	Apotex Pharmachem Inc.	Processes for the preparation of rivaroxaban and intermediates thereof
US8309547B2 (en) *	2009-04-28	2012-11-13	Apotex Pharmachem Inc.	Processes for the preparation of rivaroxaban and intermediates thereof
WO2011012321A1 (en)	2009-07-31	2011-02-03	Krka, D.D., Novo Mesto	Processes for crystallization of rivaroxaban
CN102822167A (zh) *	2010-01-04	2012-12-12	埃南蒂亚有限公司	用于制备利伐沙班的方法及其中间体
DE102010028362A1 (de)	2010-04-29	2011-11-03	Bayer Schering Pharma Aktiengesellschaft	Herstellverfahren
EP2388260A1 (de)	2010-05-21	2011-11-23	Archimica GmbH	Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
CN102311400A (zh) *	2010-06-29	2012-01-11	翔真生物科技股份有限公司	制备5-左旋-氨甲基-3-芳基-2-恶唑烷酮类的方法
EP2404920A1 (en)	2010-07-06	2012-01-11	Sandoz AG	Crystalline form of Rivaroxaban dihydrate
US20130253187A1 (en) *	2010-09-14	2013-09-26	Medichem, S.A.	Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative
CZ2010714A3 (cs) *	2010-09-30	2012-04-11	Farmak, A. S.	Zpusob výroby 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindol-1,3(2H)-dionu ve vysoké optické cistote
CA2815063C (en)	2010-10-18	2016-11-22	Apotex Pharmachem Inc.	Processes for the preparation of rivaroxaban and intermediates thereof
EP2705028B1 (en) *	2011-05-06	2019-08-21	Egis Gyógyszergyár Zrt.	Process for the preparation of a rivaroxaban and intermediates formed in said process
WO2012156983A1 (en) *	2011-05-16	2012-11-22	Symed Labs Limited	Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
ES2395304B1 (es)	2011-05-20	2014-01-16	Interquim, S.A.	Procedimiento de obtención de una tiofen-2-carboxamida.
CN102250076A (zh) *	2011-05-27	2011-11-23	横店集团家园化工有限公司	一种利伐沙班中间体及利伐沙班的制备方法
CN102827154B (zh) *	2011-06-14	2015-04-22	上海科胜药物研发有限公司	一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法
WO2013098833A2 (en)	2011-09-08	2013-07-04	Cadila Healthcare Limited	Processes and intermediates for preparing rivaroxaban
WO2013053739A1 (en)	2011-10-10	2013-04-18	Laboratorios Lesvi, S. L.	Process for preparing factor xa inhibitors
WO2013121436A2 (en) *	2012-02-06	2013-08-22	Megafine Pharma (P) Ltd	A process for preparation of rivaroxaban and intermediates thereof
CZ2012114A3 (cs) *	2012-02-17	2013-02-20	Zentiva, K.S.	Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu
CN103288814B (zh)	2012-02-24	2016-07-06	国药集团国瑞药业有限公司	一种利伐沙班中间体的制备方法
CN102659756A (zh) *	2012-04-01	2012-09-12	南京哈柏医药科技有限公司	5-氯-2-酰氯噻吩的合成方法
EP2834235A1 (en)	2012-04-06	2015-02-11	Indiana University Research and Technology Corporation	Processes for preparing rivaroxaban
BR112014027248B1 (pt)	2012-05-02	2021-01-26	Symed Labs Limited	processo em um único recipiente para preparar rivaroxaban
CN102757424B (zh) *	2012-07-09	2014-10-15	云南大学	2-苄基取代苯并呋喃—咪唑盐类化合物及其制备方法
CN102746288B (zh) *	2012-07-24	2015-04-08	常州制药厂有限公司	一种抗凝血药及其关键中间体的制备方法
WO2014020458A1 (en) *	2012-08-01	2014-02-06	Alembic Pharmaceuticals Limited	Improved process for preparation of rivaroxaban
CN102786516B (zh) *	2012-08-21	2014-10-01	湖南师范大学	一种利伐沙班的合成方法
CN103833724A (zh) *	2012-11-20	2014-06-04	上海医药工业研究院	一种5-氯噻吩-2-甲酰氯的制备方法
CN103864772A (zh) *	2012-12-13	2014-06-18	北京京卫信康医药科技发展有限公司	一种利伐沙班及其中间体的制备方法
CN103864771A (zh) *	2012-12-13	2014-06-18	北京京卫信康医药科技发展有限公司	一种利伐沙班的制备方法
WO2014096214A1 (en) *	2012-12-21	2014-06-26	Farma Grs, D.O.O.	A process for preparation of rivaroxaban
DK2895176T3 (da)	2012-12-26	2017-01-30	Wanbury Ltd	Rivaroxabanmellemprodukt og fremstilling heraf
IN2012MU03359A (da)	2012-12-26	2015-06-26	Wanbury Ltd
IN2013MU01113A (da)	2013-03-25	2015-06-19	Glenmark Generics Ltd
CN104109158A (zh) *	2013-04-16	2014-10-22	上海医药工业研究院	一种纯化利伐沙班的方法
CN103275061A (zh) *	2013-06-04	2013-09-04	上海同昌生物医药科技有限公司	一种生产5-氯噻吩-2-羧酸的方法
CN103351385A (zh) *	2013-06-28	2013-10-16	浙江燎原药业有限公司	一种利伐沙班中间体的制备方法
CN103709116B (zh) *	2013-12-10	2015-09-23	四川大学	一种4-(4-烷氧羰氨基)苯基-3-吗啉酮的制备方法
CN103724336B (zh) *	2013-12-24	2015-10-21	悦康药业集团有限公司	一种新型抗凝血药物的合成方法
WO2015104605A1 (en)	2014-01-08	2015-07-16	Wockhardt Limited	A process for preparing rivaroxaban or a pharmaceutically acceptable salt thereof
IN2014CH00290A (da)	2014-01-23	2015-08-14	Symed Labs Ltd
CN105085370B (zh) *	2014-04-22	2017-04-12	北大方正集团有限公司	(s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法
CN105693746B (zh) *	2014-06-14	2018-09-14	广东东阳光药业有限公司	噁唑烷酮类化合物的制备方法及其中间体
CN104086539A (zh) *	2014-07-17	2014-10-08	天津炜捷制药有限公司	一种利伐沙班的制备方法
CN104211693B (zh) *	2014-08-07	2017-02-22	成都百裕制药股份有限公司	一种利伐沙班晶型及其制备方法与用途
CN104211694A (zh) *	2014-08-14	2014-12-17	广东东阳光药业有限公司	一种改进的制备Xa因子抑制剂的方法
WO2016030669A1 (en) *	2014-08-25	2016-03-03	Cipla Limited	Process for the preparation of rivaroxaban
PL3209661T3 (pl)	2014-10-22	2021-08-16	Zakłady Farmaceutyczne Polpharma Sa	Sposób wytwarzania polimorfu rywaroksabanu
CN104807934B (zh) *	2015-04-30	2017-01-18	成都百裕制药股份有限公司	异吲哚二酮类化合物的正相高效液相色谱检测方法
CN105130976A (zh) *	2015-08-26	2015-12-09	浙江车头制药股份有限公司	一种利伐沙班中间体的合成方法
CN105440028B (zh) *	2015-12-07	2018-03-13	石家庄康贺威药业有限公司	一种利伐沙班化合物及其制备方法
CN106008490B (zh) *	2016-01-11	2019-01-04	南京生命能科技开发有限公司	一种利伐沙班的新晶体及其制备方法
CN106977507A (zh) *	2017-04-21	2017-07-25	上海华源医药科技发展有限公司	一种利伐沙班的制备方法
CN109553611A (zh) *	2017-09-23	2019-04-02	齐鲁制药有限公司	利伐沙班中间体的制备方法和用途
JP7205529B2 (ja) *	2018-02-26	2023-01-17	住友化学株式会社	オキサゾリジノン化合物の製造方法
JP7339754B2 (ja) *	2019-03-27	2023-09-06	ダイト株式会社	中間体の製造方法
CN112521380A (zh) *	2020-12-14	2021-03-19	哈尔滨珍宝制药有限公司	一种利伐沙班中间体a的合成方法及其在制备利伐沙班中的应用
CA3217271A1 (en) *	2021-05-28	2022-12-01	Yonggang Chen	Synthesis of btk inhibitor and intermediates thereof
EP4201933A1 (en) *	2021-12-23	2023-06-28	Zaklady Farmaceutyczne Polpharma S.A.	Crystallisation process for rivaroxaban

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19962924A1 (de) *	1999-12-24	2001-07-05	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) *	2001-06-20	2003-01-02	Bayer Ag	Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) *	2003-01-07	2004-07-15	Bayer Healthcare Ag	Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid

2004
- 2004-01-15 DE DE102004002044A patent/DE102004002044A1/de not_active Withdrawn
- 2004-12-29 GT GT200400277A patent/GT200400277A/es unknown
- 2004-12-31 SI SI200431764T patent/SI1720866T1/sl unknown
- 2004-12-31 RU RU2006129341/04A patent/RU2383540C2/ru not_active IP Right Cessation
- 2004-12-31 PT PT04804455T patent/PT1720866E/pt unknown
- 2004-12-31 DK DK04804455.6T patent/DK1720866T3/da active
- 2004-12-31 NZ NZ548506A patent/NZ548506A/en not_active IP Right Cessation
- 2004-12-31 ES ES04804455T patent/ES2369140T3/es not_active Expired - Lifetime
- 2004-12-31 EP EP04804455A patent/EP1720866B1/de not_active Expired - Lifetime
- 2004-12-31 AT AT04804455T patent/ATE518856T1/de active
- 2004-12-31 KR KR1020127018712A patent/KR20130004257A/ko not_active Ceased
- 2004-12-31 CN CN200480040552XA patent/CN1906191B/zh not_active Expired - Lifetime
- 2004-12-31 CA CA2553237A patent/CA2553237C/en not_active Expired - Lifetime
- 2004-12-31 BR BRPI0418405A patent/BRPI0418405B8/pt not_active IP Right Cessation
- 2004-12-31 AU AU2004313694A patent/AU2004313694B2/en not_active Expired
- 2004-12-31 PL PL04804455T patent/PL1720866T3/pl unknown
- 2004-12-31 JP JP2006548182A patent/JP5311742B2/ja not_active Expired - Lifetime
- 2004-12-31 WO PCT/EP2004/014870 patent/WO2005068456A1/de not_active Ceased
- 2004-12-31 HR HR20110796T patent/HRP20110796T1/hr unknown
2005
- 2005-01-10 US US11/032,815 patent/US7351823B2/en active Active
- 2005-01-12 UY UY28718A patent/UY28718A1/es not_active IP Right Cessation
- 2005-01-13 MY MYPI20050142A patent/MY138944A/en unknown
- 2005-01-13 HN HN2005000016A patent/HN2005000016A/es unknown
- 2005-01-14 PE PE2005000062A patent/PE20050763A1/es active IP Right Grant
- 2005-01-14 TW TW094101059A patent/TWI340137B/zh not_active IP Right Cessation
- 2005-01-14 AR ARP050100147A patent/AR047389A1/es not_active Application Discontinuation
2006
- 2006-07-10 IL IL176767A patent/IL176767A/en active IP Right Grant
- 2006-07-10 MA MA29179A patent/MA28290A1/fr unknown
- 2006-07-12 ZA ZA200605747A patent/ZA200605747B/en unknown
- 2006-07-14 EC EC2006006703A patent/ECSP066703A/es unknown
- 2006-08-15 NO NO20063677A patent/NO335553B1/no unknown
2011
- 2011-10-27 CY CY20111101020T patent/CY1112565T1/el unknown
- 2011-12-27 JP JP2011286538A patent/JP2012097106A/ja active Pending

Also Published As

Publication number	Publication date
HRP20110796T1 (hr)	2011-12-31
RU2383540C2 (ru)	2010-03-10
AU2004313694A1 (en)	2005-07-28
AR047389A1 (es)	2006-01-18
BRPI0418405B1 (pt)	2018-03-13
CN1906191B (zh)	2010-05-26
TWI340137B (en)	2011-04-11
EP1720866B1 (de)	2011-08-03
UY28718A1 (es)	2005-08-31
JP2012097106A (ja)	2012-05-24
ES2369140T3 (es)	2011-11-25
NO335553B1 (no)	2014-12-29
WO2005068456A1 (de)	2005-07-28
CA2553237A1 (en)	2005-07-28
EP1720866A1 (de)	2006-11-15
KR20130004257A (ko)	2013-01-09
NO20063677L (no)	2006-10-11
RU2006129341A (ru)	2008-02-20
US20050182055A1 (en)	2005-08-18
JP5311742B2 (ja)	2013-10-09
PE20050763A1 (es)	2005-12-02
CY1112565T1 (el)	2016-02-10
US7351823B2 (en)	2008-04-01
CA2553237C (en)	2012-04-17
SI1720866T1 (sl)	2012-01-31
MA28290A1 (fr)	2006-11-01
HK1103722A1 (en)	2007-12-28
DE102004002044A1 (de)	2005-08-04
PL1720866T3 (pl)	2012-01-31
PT1720866E (pt)	2011-10-12
JP2007517816A (ja)	2007-07-05
MY138944A (en)	2009-08-28
ZA200605747B (en)	2007-10-31
HN2005000016A (es)	2009-06-01
NZ548506A (en)	2009-06-26
ECSP066703A (es)	2006-10-31
CN1906191A (zh)	2007-01-31
TW200604195A (en)	2006-02-01
IL176767A0 (en)	2006-10-31
AU2004313694B2 (en)	2011-06-02
BRPI0418405A (pt)	2007-05-15
BRPI0418405B8 (pt)	2021-05-25
GT200400277A (es)	2005-08-18
IL176767A (en)	2011-04-28
ATE518856T1 (de)	2011-08-15

Publication	Publication Date	Title
CY2022001I1 (el)	2022-03-24	Παραγωγα του uk-2a
DK1720866T3 (da)	2011-11-21	Fremgangsmåde
CY2019034I2 (el)	2019-11-27	4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια
DE602005015457D1 (de)	2009-08-27	Ungselements
EP1814610A4 (en)	2011-03-09	Catheter insertion apparatus
DE502005005628D1 (de)	2008-11-20	Wischblatt
DE602005025468D1 (de)	2011-02-03	Gssystem
DE602004029102D1 (de)	2010-10-21	Spiegelwinkeleinstellvorrichtung
DE602005022258D1 (de)	2010-08-26	Perfluoroelastomere
DE602004004628D1 (de)	2007-03-22	Schlauchendsprühgerät
DE602005001374D1 (de)	2007-07-26	Spurabweichwarnung
DE602004017368D1 (de)	2008-12-04	Verschliessmaschinenkopf
DE502005003777D1 (de)	2008-05-29	Thiazolyl-dihydro-indazole
DE502005004843D1 (de)	2008-09-04	Einspritzventil
DE602005007966D1 (de)	2008-08-21	Reifenabdrückvorrichtung
DE602005010002D1 (de)	2008-11-13	Neigungverstellvorrichtung
NO20043305D0 (no)	2004-08-09	Preparation of lodixanol
DE602005018298D1 (de)	2010-01-28	Schwingarmstruktur
DE502004006772D1 (de)	2008-05-21	Wirkwerkzeug-Barre
PT1763520E (pt)	2009-03-23	Utilização de benzopiranonas trissubstituídas
EP1793396A4 (en)	2007-11-21	Leakage transformer
FR2877833B1 (fr)	2007-10-12	Correcteur de lordoses
FR2865904B1 (fr)	2006-06-30	Calecon remonte fesses
DE502005005805D1 (de)	2008-12-11	Remsanlage
DE602004011046D1 (de)	2008-02-14	Divinylfluorene